COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #101 of 230
8/2 Late treatment study
Davido et al., Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129 (Peer Reviewed)
Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Source   PDF   Share   Tweet
Retrospective of 132 hospitalized patients. HCQ+AZ(52)/AZ(28) significantly reduced death/ICU, HR=0.45, p=0.04. Adjusted for Charlson Comorbidity Index (including age), obesity, O2, lymphocyte count, and treatments. Mean delay from admission to treatment 0.7 days.

Davido et al., 8/2/2020, retrospective, France, Europe, peer-reviewed, 14 authors.
risk of combined intubation/hospitalization, 55.0% lower, RR 0.45, p = 0.04, treatment 12 of 80 (15.0%), control 13 of 40 (32.5%).
Details of all 230 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit